摘要
目的 诺维本加顺铂(NP)和健择加顺铂(GP)方案均是目前治疗晚期非小细胞肺癌的常用方案,本研究对两种方案进行了有效率、存活率和不良反应等方面的比较。方法 自1999~2004年,总共80例晚期非小细胞肺癌(Ⅲb期或Ⅳ期)参与研究,采用NP方案治疗40例、GP方案40例,比较其疗效及不良反应。结果 总有效率NP方案为27.5%,GP方案为22.5%(P〉0.05);平均存活时间NP方案为9.4个月,GP方案为8.6个月(P〉0.05);1年存活率NP方案为10.0%,GP方案为7.5%(P〉0.05)。两种方案的主要不良反应均为骨髓抑制,白细胞下降至Ⅲ、Ⅳ度者NP方案为45%,GP方案为40%(P〉0.05);化疗后出现Ⅲ、Ⅳ度便秘者NP方案为25.0%,GP方案为7.5%(P〈0.05)。结论 NP方案和GP方案治疗晚期非小细胞肺癌效果确实,且较一致,耐受性均较好,但使用NP方案要注意预防便秘。
Objective The combinations of vinorelbine plus cisplatin(NP) and gemcitabine plus cisplatin(GP) are good regimens used in the treatment of advanced non-small cell lung cancer(NSCLC). To compare the response rate, survival rate and toxicity of the two regimens. Methods From 1999 to 2004,80 patients with a mean age of 56.2 years (range 26-77 years)with Ⅲ b/Ⅳ stage NSCLC were treated with vinorelbine (VNR,25mg/m^2) on ld and 8d and cisplatin (CDDP,30mg/m^2) on ld,2d and 3d or gemcitabine (GEM, 1 000mg/m^2 ) on ld and 8d and cisplatin (CDDP,30mg/m^2 ) on 1d,2d and 3d,in repeated cycle of 21d. Fourty patients (group A) received NP and 40(group B) received GP. Results In group A, there were 1 complete recovery(CR) and 10 partial recovery(PR) with the overall response rate (ORR) of 27.5%, compared with 9 PR and ORR of 22.5% in group B(P〉0.05). Mean survival times were 9.4 months in group A and 8.6 months in group B(P〉0.05). One-year survival rates for group A and B were 10.0% and 7.5% respectively. The main side effects came from the inhibition on the bone marrow. The grade Ⅲ , Ⅳ of leukopenia in group A and B were 45.0% and 40.0% respectively. There was no significant difference between the two groups(P〉0.05). The grade Ⅲ , Ⅳ of constipation in group A and B were 25.0 % and 7.5 % respectively. There was significant difference between the two groups(P〈0.05). Conclusion Both NP and GP are tolerable regimens with good efficacy for advanced NSCLC patients.
出处
《重庆医学》
CAS
CSCD
2007年第6期521-523,共3页
Chongqing medicine
关键词
健择
诺维本
顺铂
非小细胞肺癌
联合化疗
vinorelbine
gemcitabine
gsplatin
Non-small cell lung cancer
combined chemotherapy